Minimal Residual Disease in Chronic Lymphocytic Leukemia: A New Goal?

In chronic lymphocytic leukemia (CLL), there is a growing interest for minimal residual disease (MRD) monitoring, due to the availability of drug combinations capable of unprecedented complete clinical responses. The standardized and most commonly applied methods to assess MRD in CLL are based on fl...

Descripción completa

Detalles Bibliográficos
Autores principales: Del Giudice, Ilaria, Raponi, Sara, Della Starza, Irene, De Propris, Maria Stefania, Cavalli, Marzia, De Novi, Lucia Anna, Cappelli, Luca Vincenzo, Ilari, Caterina, Cafforio, Luciana, Guarini, Anna, Foà, Robin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6727319/
https://www.ncbi.nlm.nih.gov/pubmed/31555576
http://dx.doi.org/10.3389/fonc.2019.00689

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6727319/
https://www.ncbi.nlm.nih.gov/pubmed/31555576
http://dx.doi.org/10.3389/fonc.2019.00689

Ejemplares similares